Your browser doesn't support javascript.
Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in.
Pugliatti, Maura; Hartung, Hans-Peter; Oreja-Guevara, Celia; Pozzilli, Carlo; Airas, Laura; Alkhawajah, Mona; Grigoriadis, Nikolaos; Magyari, Melinda; Van Wijmeersch, Bart; Zakaria, Magd; Linker, Ralf; Chan, Andrew; Vermersch, Patrick; Berger, Thomas.
  • Pugliatti M; Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy.
  • Hartung HP; Interdepartmental Center of Research for Multiple Sclerosis and Neuro-inflammatory and Degenerative Diseases, University of Ferrara, Ferrara, Italy.
  • Oreja-Guevara C; Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
  • Pozzilli C; Brain and Mind Center, University of Sydney, Sydney, NSW, Australia.
  • Airas L; Department of Neurology, Palacky University Olomouc, Olomouc, Czechia.
  • Alkhawajah M; Department of Neurology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
  • Grigoriadis N; Faculty of Medicine, Complutense University of Madrid (UCM), Madrid, Spain.
  • Magyari M; Multiple Sclerosis Center, S. Andrea Hospital, Department of Human Neuroscience, University Sapienza, Rome, Italy.
  • Van Wijmeersch B; Division of Clinical Neurosciences, University of Turku, Turku, Finland.
  • Zakaria M; Neurocenter of Turku University Hospital, Turku, Finland.
  • Linker R; Section of Neurology, Neurosciences Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • Chan A; College of Medicine, Al Faisal University, Riyadh, Saudi Arabia.
  • Vermersch P; Laboratory of Experimental Neurology and Neuroimmunology, Second Department of Neurology, American Hellenic Educational Progressive Association (AHEPA) University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Berger T; Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Front Immunol ; 13: 1045101, 2022.
Article in English | MEDLINE | ID: covidwho-2099155
ABSTRACT
It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.1045101

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.1045101